Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: Long-term results

Authors
Locatelli, MC Facendola, G Pizzocaro, G Piva, L Pegoraro, C Pallavicini, EB Signaroldi, A Meregalli, M Lombardi, F Beretta, GD Scanzi, F Labianca, R Dallavalle, G Luporini, G
Citation
Mc. Locatelli et al., Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: Long-term results, CANCER DET, 23(2), 1999, pp. 172-176
Citations number
15
Categorie Soggetti
Oncology
Journal title
CANCER DETECTION AND PREVENTION
ISSN journal
0361090X → ACNP
Volume
23
Issue
2
Year of publication
1999
Pages
172 - 176
Database
ISI
SICI code
0361-090X(1999)23:2<172:SAOIAI>2.0.ZU;2-2
Abstract
Clinical data have supported the combination of subcutaneous r-interleukin- 2 (rIL-2) and r-interferon-alpha (rIFN-alpha) as a promising combination fo r advanced renal cell carcinoma (RCC), with a reduced toxicity, Mle evaluat ed the activity and safety of this outpatient immunotherapy and report on t he clinical results and the long-term. survival analysis. Objective respons es was observed in 9 of 50 (18%) patients, 6 of whom (12%) achieved a compl ete response. Overall median survival is 12 months; six patients were survi ving at a median follow-up of 24 months, and three (6%) are still progressi on-free.